Skip to main content
C.Q. Pharmaceutical Holding Co., Ltd. logo

C.Q. Pharmaceutical Holding Co., Ltd. — Investor Relations & Filings

Ticker · 000950 ISIN · CNE0000010K0 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 2,883 across all filing types
Latest filing 2024-04-26 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000950

About C.Q. Pharmaceutical Holding Co., Ltd.

https://www.cqphar.com

C.Q. Pharmaceutical Holding Co., Ltd. is a comprehensive pharmaceutical enterprise specializing in the distribution, retail, and supply chain management of healthcare products. The company operates an extensive network focused on the wholesale of pharmaceuticals and medical devices, providing integrated logistics and warehousing solutions to healthcare providers and manufacturers. Its core business activities encompass the procurement and distribution of a wide range of prescription drugs, over-the-counter medications, and specialized medical equipment. Through its retail pharmacy operations and third-party logistics services, the company facilitates the efficient delivery of medical supplies. C.Q. Pharmaceutical Holding Co., Ltd. emphasizes technological integration within its supply chain to optimize inventory management and ensure the integrity of healthcare products throughout the distribution lifecycle.

Recent filings

Filing Released Lang Actions
关于重药控股股份有限公司2023年度涉及财务公司关联交易的存款、贷款等金融业务的专项说明
Audit Report / Information Classification · 95% confidence The document is a detailed special explanation report regarding related-party financial transactions involving deposits and loans with a financial company for the fiscal year 2023. It includes references to audited financial statements, audit opinions, and compliance with regulatory requirements from Chinese regulatory bodies such as the China Securities Regulatory Commission and the Shenzhen Stock Exchange. The document contains financial data tables, audit certifications, and is prepared by the company's management and auditors. It is not a full annual report but a standalone audit-related report focusing on specific financial transactions and audit verification. The document length is over 6,000 characters and contains substantive financial data and audit information, indicating it is not merely an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR).
2024-04-26 Chinese
董事会对独立董事独立性评估的专项意见
Board/Management Information Classification · 95% confidence The document is a special opinion from the board of directors regarding the independence evaluation of the company's independent directors. It references regulatory guidelines related to independent directors and confirms their independence status. The document is short (472 characters) and does not contain financial data, financial results, or detailed management discussion. It is not an annual report, audit report, or earnings release. It is also not a regulatory filing or certification letter but a formal board opinion on governance matters. This fits best under Board/Management Information (MANG), which includes announcements related to board members and management. Confidence is high due to clear content and context.
2024-04-26 Chinese
2023年度独立董事述职报告-陈逢文
Board/Management Information Classification · 95% confidence The document is a detailed 2023 annual performance report by an independent director of the company, describing their duties, attendance at meetings, compliance with laws and regulations, and overall evaluation and suggestions. It is a formal report on the director's activities and governance role rather than a financial report, audit, or announcement. It does not contain financial statements or earnings data, nor is it a brief announcement or proxy material. The content aligns with a Management Report or similar governance-related report, but since it focuses on the independent director's duties and governance oversight, it fits best under Board/Management Information (MANG). The document length is 3317 characters, which is consistent with a detailed report but not a full annual report or audit report. Therefore, the classification is MANG with high confidence.
2024-04-26 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 9th Board of Directors' 5th meeting of Chongqing Pharmaceutical Holdings Co., Ltd. It includes approvals of various reports such as the 2023 Annual Report, 2023 Annual Financial Statements, 2024 Budget, ESG Report, and others. The document also mentions that these reports are disclosed simultaneously with this announcement and that the resolutions will be submitted to the shareholders' meeting for approval. The document itself is a board meeting resolution announcement, not the actual reports or financial statements. It is relatively short (2880 characters) and primarily serves to inform about the board's decisions and approvals. Therefore, it fits best into the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board, including meeting resolutions.
2024-04-26 Chinese
2023年度独立董事述职报告-赵建新（已离任）
Board/Management Information Classification · 95% confidence The document is a detailed 2023 annual performance report of an independent director of a company, describing the director's duties, attendance, oversight activities, and evaluations related to governance and compliance. It is not a financial report, audit report, or earnings release, but rather a management-related report focusing on the director's role and governance oversight. It does not announce voting results, changes in management, or legal proceedings. The content aligns with a Board/Management Information type filing, specifically reporting on the independent director's annual duties and activities.
2024-04-26 Chinese
关于计提减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by the company regarding the provision for asset impairment, including detailed figures on impairment losses for various asset categories such as receivables, inventory, and goodwill. It references accounting standards and the impact on the company's financial results for the year ending December 31, 2023. The document is relatively short (2236 characters) and serves as a formal disclosure of impairment provisions rather than a full financial report. It does not contain comprehensive financial statements or detailed analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a certification or a regulatory compliance filing. The content fits best with a Regulatory Filing (RNS) as it is a specific announcement about accounting estimates and provisions without being a full report or presentation.
2024-04-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.